Dr Munshi on the Final Results of the CARTITUDE-1 Trial of C

Nikhil C. Munshi, MD, discusses the efficacy data from the final analysis of the phase 1b/2 CARTITUDE-1 trial of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.

Related Keywords

, Nikhilc Munshi , Dana Farber Cancer Institute , Medicine At Harvard Medical School , Correlative Science , Jerome Lipper Multiple Myeloma Center , Kraft Family Chair , Multiple Myeloma Immune Effector Cell Therapy , Harvard Medical School ,